New drug cocktail shows promise in Tough-to-Treat prostate cancer
NCT ID NCT05730712
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two targeted drugs (pertuzumab and trastuzumab) plus a chemotherapy drug (enzalutamide) in 7 men with advanced prostate cancer that had stopped responding to standard treatments. The goal was to see if the combination could shrink or slow the growth of tumors. The approach uses antibodies to block cancer growth signals and chemotherapy to kill cancer cells.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a three-drug cocktail outsmart resistant prostate cancer?
- Precision radiation may tame rising PSA after prostate surgery
- Blood test could tell doctors when to stop prostate cancer treatment early
- Could a stronger first dose of targeted radiation beat back advanced prostate cancer?
- Targeted radiation plus hormone therapy may slow Low-Volume prostate cancer spread